Neratinib is indicated for the extended adjuvant treatment of adults with early-stage hormone receptor-positive, HER2-overexpressed/amplified breast cancer and who completed adjuvant trastuzumab-based therapy less than one year ago.
|NCPE Assessment Process||Complete|
|Rapid review commissioned||18/12/2019|
|Rapid review completed||30/01/2020|
|Rapid Review outcome||A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of neratinib compared with the current standard of care.
|Full pharmacoeconomic assessment commissioned by the HSE||05/02/2020|
|Pre-submission consultation with Applicant||21/04/2020|
|Initial submission received from Applicant||14/07/2020|
|Current status||Initial submission received from Applicant|